Diplomat Pharmacy Inc Makes Up for Lost Contracts
Diplomat Pharmacy (NYSE: DPLO) lost some contracts and gained some others, which netted out to slightly higher revenue in the second quarter. Operating income and earnings weren't nearly as flat, but that was because of higher acquisition-associated costs.
Metric
Q2 2017
Source: Fool.com